Asarina Pharma ApS - CVR: 38495712

2023, DKK

17.07.2024

Bruttoresultat

-884'

Primær drift

-44.107'

Årets resultat

-42.903'

Aktiver

2.490'

Kortfristede aktiver

1.972'

Egenkapital

1.226'

Afkastningsgrad

-1771 %

Soliditetsgrad

49 %

Likviditetsgrad

156 %

Resultat

17.07.2024

Årsrapport	2023 17.07.2024	2022 14.07.2023	2021 12.05.2022	2020 28.04.2021
Nettoomsætning
Bruttoresultat	-884.336	-508.850	-887.274	-1.890.785
Resultat af primær drift	-44.107.270	-10.865.727	-29.512.554	-56.242.431
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0
Finansielle indtægter	80.534	63.246	169.068	247.869
Finansieringsomkostninger	-52.189	-94.617	-228.806	-1.033.684
Andre finansielle omkostninger	0	0	0	0
Resultat før skat	-44.078.925	-10.897.098	-29.572.292	-57.028.246
Resultat	-42.903.193	-9.822.821	-24.704.716	-51.528.246
Forslag til udbytte	0	0	0	0

Aktiver

17.07.2024

Årsrapport	2023 17.07.2024	2022 14.07.2023	2021 12.05.2022	2020 28.04.2021
Kortfristede varebeholdninger	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	1.248.880	1.104.710	0	5.580.759
Likvider	722.757	4.957.238	3.854.290	9.920.555
Kortfristede aktiver	1.971.637	0	8.830.735	15.501.314
Immaterielle aktiver og goodwill	0	36.779.560	0	44.725.336
Finansielle anlægsaktiver	13.614	18.575	0	22.629
Materielle aktiver	505.164	789.396	0	1.357.861
Langfristede aktiver	518.778	37.587.531	41.848.706	46.105.826
Aktiver	2.490.415	43.649.479	50.679.441	61.607.140

Aktiver

17.07.2024

Passiver

17.07.2024

Årsrapport	2023 17.07.2024	2022 14.07.2023	2021 12.05.2022	2020 28.04.2021
Forslag til udbytte	0	0	0	0
Egenkapital	1.225.889	42.708.929	48.991.408	44.077.253
Hensatte forpligtelser	0	0	0	0
Langfristet gæld til banker	0	0	0	0
Anden langfristet gæld		0	0	0
Leverandører af varer og tjenesteydelser	140.809	320.439	1.220.241	8.105.968
Kortfristede forpligtelser	1.264.526	940.550	0	9.213.697
Gældsforpligtelser	1.264.526	940.550	1.688.033	17.529.887
Forpligtelser	1.264.526	940.550	1.688.033	17.529.887
Passiver	2.490.415	43.649.479	50.679.441	61.607.140

Passiver

17.07.2024

Nøgletal

17.07.2024

Årsrapport	2023 17.07.2024	2022 14.07.2023	2021 12.05.2022	2020 28.04.2021
Afkastningsgrad	-1.771,1 %	-24,9 %	-58,2 %	-91,3 %
Dækningsgrad	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-3.499,8 %	-23,0 %	-50,4 %	-116,9 %
Payout-ratio	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-84.514,5 %	-11.483,9 %	-12.898,5 %	-5.441,0 %
Soliditestgrad	49,2 %	97,8 %	96,7 %	71,5 %
Likviditetsgrad	155,9 %	Na.	Na.	168,2 %

Resultat

17.07.2024

Gæld

17.07.2024

Årsrapport

17.07.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 17.07.2024)

Information om virksomhedens regnskabsklasse:The annual report of Asarina Pharma ApS for 2023 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Beretning

17.07.2024

Dato for ledelsens godkendelse af årsrapporten:2024-07-10

Ledelsespåtegning:Statement by the Board of Directors and the Executive Board

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Asarina Pharma ApS for the financial year 1 January ‑ 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Business reviewAsarina Pharma ApS (“the Company”) was established by Asarina Pharma AB (Sweden) on 16 March 2017 through contribution‑in‑kind of certain intangible assets. The Company is the operating vehicle for the R&D activities in the Asarina Pharma Group (“Asarina”). Asarina is developing novel pharmaceutical products, including its lead compound, Sepranolone, for treatment of neurological diseases such as Tourette Syndrome, with the aim to enable patients to remain in control of their life. On 1 April 2023, the Company announced results of its phase IIa study with Sepranolone in Tourette Syndrome. The results showed improvements in all clinical parameters in the patients receiving Sepranolone versus the control group. Since completing the phase IIa study in April 2023, the Company has focused on finding a partner who can bring Sepranolone into the next clinical phase. The Company will continue to explore the potential for a partnership, i. e. a sale or out‑licensing of its IP assets. Considering the uncertainty associated with the partnering process, Management has identified impairment indications of the intangible assets, and impaired the value to DKK 0 considering the highest amount of the value in use and sales value less cost to dispose. Since such new funding has not been obtained as of the date of these Financial Statements, material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern exists, and as such, also material uncertainty as to the valuation of the Company’s intangible assets. Reference is also made to note 2 regarding going concern. Unusual matters having affected the financial statements